Author(s) Details:
Alexandru Calin Grigorescu
Compartment of Medical Oncology, Clinical Hospital for Nephrology “Dr Carol Davila”, Calea Grivitei Nr4, Bucharest, Romania
This section is a part of the chapter: Tirosine Kinase Inhibitors (TKI) Used in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Based on Specific Genetic Alterations
Osimertinib is the first third-generation E GRF-TKI approved for the treatment of NSCLC. An important study that defined the role of Osimertinib in the treatment of NSCLC was the AURA3 study. In this study, progression-free survival (PFS) was significantly prolonged in the Osimertinib arm and the response rate was also significantly improved compared to platinum-pemetrexed chemotherapy in patients with centrally confirmed EGFR T790M advanced NSCLC and progression on first-line EGFR-TKI therapy. Overall survival data were not significant in favor of the osimertinib arm, likely due to the study design involving a high crossover rate of osimertinib therapy and chemotherapy (Wu et al., 2019).
“Another approval for Osimertinib was in the adjuvant setting, as on December 18, 2020, the Food and Drug Administration approved Osimertinib for the adjuvant treatment of patients with NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations. Detection of the EGFR mutation was done using FDA-approved tests” (U.S. Food & Drug Administration, 2025).
How to Cite
Nasrat, A. M., Nasrat, S. A., Nasrat, R. M., Nasrat, M. M., & Babiker, S. Y. (2025). Helicobacter pylori and Hyperuricemia: Revisiting Gout Diagnosis in Young Adults with Normal Renal Function. Medical Science: Trends and Innovations Vol. 4, 1–8. https://doi.org/10.9734/bpi/msti/v4/3641